已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Antibody–drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges

作者
Yilin Zhao,Xiaoran Ma,Xiaozhen Liu,Li Yan
出处
期刊:Cancer Chemotherapy and Pharmacology [Springer Science+Business Media]
卷期号:96 (1)
标识
DOI:10.1007/s00280-026-04964-z
摘要

Antibody-drug conjugates (ADCs) are designed to deliver cytotoxic agents directly to tumor cells by conjugating an antigen-specific monoclonal antibody with a potent payload. By recognizing tumor-associated antigens and undergoing intracellular processing, ADCs enhance antitumor activity while minimizing damage to normal tissues. This review focuses on the research progress of ADCs targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), providing an in-depth analysis of their mechanisms of action, molecular design, and clinical efficacy, with particular emphasis on novel ADCs targeting HER2, TROP2, and DLL3. Despite challenges such as target specificity and drug resistance, clinical trial data demonstrate that ADCs exhibit significant therapeutic efficacy in the treatment of both NSCLC and SCLC. The article also discusses emerging strategies to overcome current limitations, including innovative linker technologies, development of bispecific ADCs, and exploration of combination treatment plans. Given that lung cancer is the leading cause of cancer-related mortality worldwide, ADCs technology holds promise for delivering breakthrough advances in improving therapeutic outcomes and alleviating the societal burden of the disease. With ongoing research into ADCs, future clinical applications may provide more precise and effective treatment options for patients with lung cancer. Landscape of antibody-drug conjugate (ADC) targets, payload classes, and clinical-development maturity in lung cancer. ADC targets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are categorized according to representative cytotoxic payload classes and overall clinical development maturity. In NSCLC, HER2 and TROP2 represent the most clinically advanced ADC targets, while HER3, c-MET, and CEACAM5 remain under active clinical investigation. In SCLC, DLL3, SEZ6, and B7-H3 have emerged as promising therapeutic targets with distinct developmental trajectories. Payload classes are grouped according to mechanism of action, including topoisomerase I inhibitors, DNA alkylators, and microtubule inhibitors. Development maturity is indicated by a four-dot scale representing approved/established, late-stage clinical, early-to-mid clinical, and exploratory/emerging stages.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
三月完成签到 ,获得积分10
刚刚
干净书翠发布了新的文献求助10
刚刚
路漫漫123完成签到,获得积分10
刚刚
Hao完成签到,获得积分20
1秒前
1秒前
2秒前
3秒前
00hello00发布了新的文献求助10
3秒前
yizhiyang发布了新的文献求助10
4秒前
顾矜的应助被Panda采纳,获得10
5秒前
虚心的芝麻完成签到,获得积分10
5秒前
7秒前
Xi完成签到 ,获得积分10
7秒前
7秒前
还等雨落的应助被fizzy采纳,获得50
8秒前
10秒前
11秒前
HJJ完成签到 ,获得积分10
11秒前
初景的应助被djbj2022采纳,获得20
12秒前
15秒前
15秒前
15秒前
15秒前
虚拟的小笼包完成签到,获得积分10
16秒前
寂寞的冰蓝关注了科研通微信公众号
16秒前
ililiiris发布了新的文献求助10
17秒前
17秒前
Alice完成签到,获得积分10
18秒前
18秒前
12发布了新的文献求助10
18秒前
记忆面包完成签到 ,获得积分10
18秒前
带虾的烧麦完成签到,获得积分10
18秒前
20秒前
20秒前
小蘑菇的应助被YOUTH采纳,获得100
20秒前
沉静的元霜完成签到,获得积分10
20秒前
20秒前
Littlealpaca完成签到 ,获得积分10
20秒前
21秒前
Lucas的应助被Shirong_Peng采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194470
求助须知:如何正确求助?哪些是违规求助? 9580227
关于积分的说明 21870293
捐赠科研通 7794034
什么是DOI,文献DOI怎么找? 3437667
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484393